An interventional study of iStent inject surgery in Primary Open Angle Glaucoma (POAG), sponsored by Glaukos Corporation. Terminated at 1 site in Brazil. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2022-09-09.
Sponsored by Glaukos Corporation · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 43 studies in Glaucoma, Open-Angle by Glaukos Corporation — 7 open to participants now, 10 under way, 2 of them phase 3. Glaucoma, Open-Angle · Glaukos Corporation.
Among the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, this one is the 38th largest by enrollment of the 38 interventional ones that give a count, is one of 4 that started in 2018, is one of 15 with no phase, and was the 28th registered.
924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.
Browse Glaucoma, Open-Angle studies →7 of the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation are open now, in 1 country. Recruiting first, the newest first:
Glaukos Corporation · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 18+
Glaukos Corporation · Sites in United States
Ages 45+
By country, each count listing its studies:
Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.
This study: 18 Years and older · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
43 studies; the count open now beside each. This study's row is marked.
First in 2003; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 6 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.
Median enrollment 111 across the 38 interventional studies, 108 across the 5 observational. Of the 30 that completed or were terminated, 8 (27%) have results posted.
This tab as a report to print or save as PDF → With an account.
Glaukos Corporation is the lead sponsor of 67 studies on the registry; 14 are open to participants now.
Of its 13 completed or terminated interventional studies of FDA-regulated products, 7 (54%) have results posted.
2 of the studies in Glaucoma, Open-Angle by Glaukos Corporation that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07816692Glaukos CorporationiDose TR Administration in an Office-Based Surgery Setting | 2027-03 |
| NCT06066645Glaukos CorporationTravoprost Intraocular Implant + iStent Infinite | 2027-05 |
Add all 2 to your calendar (.ics) → With an account.
Among the 43 studies in Glaucoma, Open-Angle by Glaukos Corporation, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications.
The purpose of this study is to evaluate the intraocular pressure (IOP) lowering effect of iStent inject in eyes of subjects with primary open-angle glaucoma previously on two anti-glaucoma medications. Outcomes will be evaluated at 12 and 24 months.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Single-arm study. Intervention is micro-invasive glaucoma surgery (MIGS) to implant iStent inject
Device: iStent inject surgery
Micro-invasive glaucoma surgery (MIGS) to implant iStent inject
IOP reduction at 12 and 24 months on same number or fewer medications
IOP reduction at 12 and 24 months on same number or fewer medications
Time frame: 12 months and 24 months
Ran from Feb 2018 to primary completion in Dec 2020, 34 months.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Sep 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.